September 6th 2024
"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.
Advanced prostate cancer agent efficacious regardless of age
April 2nd 2013Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Baldness raises PCa risk in African-Americans
March 26th 2013Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, reported researchers from the University of Pennsylvania, Philadelphia.
ASTRO on proton therapy: More research needed
March 18th 2013The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.
Endocrine disruptors linked to PCa, cryptorchidism
February 25th 2013Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.
'Field effect' markers may detect occult prostate Ca
February 25th 2013Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
FDA grants priority review to metastatic PCa agent
February 19th 2013The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.